Lupin Gets USFDA Approval for Modafinil Tablets

Pharmaceutical company Lupin has received approval from the US Food and Drug Administration (USFDA) to market Modafinil tablets in the United States. The medicine is used to improve wakefulness in patients suffering from excessive sleepiness associated with narcolepsy, obstructive sleep apnoea and shift-work sleep disorder. The approval strengthens Lupin’s product portfolio in the important US pharmaceutical market. Modafinil is a generic medicine, and Lupin will manufacture and market the approved tablets in the US. The development comes as Indian pharmaceutical companies continue to expand their presence in the US through new generic drug approvals. The company has been regularly adding products to its US portfolio through regulatory approvals, helping diversify its international business. Lupin’s shares remained in focus following the announcement